Have you or your loved ones been diagnosed with primary immunodeficiency?

You may be eligible to participate in a primary immunodeficiency clinical trial.

Have you or your loved ones been diagnosed with primary immunodeficiency? You may be eligible to participate in a primary immunodeficiency clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Primary Immunodeficiency Clinical Trial
NCT03033745 | Phase 4 | Interventional
CSL Behring
Sponsored by
CSL Behring

Have you or your loved ones been diagnosed with primary immunodeficiency?

You may be eligible to participate in a primary immunodeficiency clinical trial.

Have you or your loved ones been diagnosed with primary immunodeficiency? You may be eligible to participate in a primary immunodeficiency clinical trial.

Completed

Male & Female

2 Years +

This study has recruited 49 Participants

This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID). A total of 45 subjects with confirmed PID will be evaluated in the study. During the study, the weekly dose will remain unchanged (as prescribed by treating physician, usually within 100-200 mg/kg per week range); only the respective infusion parameter under evaluation will change.